BACKGROUND: Previous studies demonstrated dysregulated expression of microRNAs (miRNAs) in the myocardium of patients with dilated cardiomyopathy (DCM). This study investigated levels of miRNAs in the circulation of DCM patients, and the value of miRNAs as biomarkers for DCM. METHODS AND MATERIALS: In 45 DCM patients and 39 age- and sex-matched controls, circulating miR-423-5p, miR-126, miR-361-5p, miR-155, and miR-146a concentrations were measured and correlated to cardiac functional parameters, including left ventricular ejection fraction (LVEF) and N-terminal pro-brain natriuretic peptide (NT-proBNP). RESULTS: Plasma levels of miR-126 and miR-361-5P did not differ between the DCM and control groups (p = 0.331 and p = 0.784, respectively). Plasma levels of the immunity-associated miRNAs, miR-146a and miR-155, did not differ between the DCM and control groups (p = 0.437 and p = 0.702, respectively). Levels of circulating miR-423-5p were significantly greater in the DCM group (p = 0.003). Further, there was a positive correlation between plasma levels of miR-423-5p and NT-proBNP (r = 0.430, p = 0.003). MiR-423-5p distinguished DCM cases from controls with an area under the curve (AUC) receiver operating characteristic (ROC) curve of 0.674 (95% CI, 0.555-0.793). CONCLUSIONS: Patients with DCM have elevated plasma miR-423-5p levels. The plasma concentration of miR-423-5p was positively correlated with the level of NT-proBNP. Circulating levels of miR-423-5p could be served as a diagnostic biomarker for heart failure caused by DCM. Plasma levels of immunity-associated miR-146a, -155, and -126 were not significantly different between DCM and control groups.
BACKGROUND: Previous studies demonstrated dysregulated expression of microRNAs (miRNAs) in the myocardium of patients with dilated cardiomyopathy (DCM). This study investigated levels of miRNAs in the circulation of DCMpatients, and the value of miRNAs as biomarkers for DCM. METHODS AND MATERIALS: In 45 DCMpatients and 39 age- and sex-matched controls, circulating miR-423-5p, miR-126, miR-361-5p, miR-155, and miR-146a concentrations were measured and correlated to cardiac functional parameters, including left ventricular ejection fraction (LVEF) and N-terminal pro-brain natriuretic peptide (NT-proBNP). RESULTS: Plasma levels of miR-126 and miR-361-5P did not differ between the DCM and control groups (p = 0.331 and p = 0.784, respectively). Plasma levels of the immunity-associated miRNAs, miR-146a and miR-155, did not differ between the DCM and control groups (p = 0.437 and p = 0.702, respectively). Levels of circulating miR-423-5p were significantly greater in the DCM group (p = 0.003). Further, there was a positive correlation between plasma levels of miR-423-5p and NT-proBNP (r = 0.430, p = 0.003). MiR-423-5p distinguished DCM cases from controls with an area under the curve (AUC) receiver operating characteristic (ROC) curve of 0.674 (95% CI, 0.555-0.793). CONCLUSIONS:Patients with DCM have elevated plasma miR-423-5p levels. The plasma concentration of miR-423-5p was positively correlated with the level of NT-proBNP. Circulating levels of miR-423-5p could be served as a diagnostic biomarker for heart failure caused by DCM. Plasma levels of immunity-associated miR-146a, -155, and -126 were not significantly different between DCM and control groups.
Authors: Stephan Fichtlscherer; Salvatore De Rosa; Henrik Fox; Thomas Schwietz; Ariane Fischer; Christoph Liebetrau; Michael Weber; Christian W Hamm; Tino Röxe; Marga Müller-Ardogan; Angelika Bonauer; Andreas M Zeiher; Stefanie Dimmeler Journal: Circ Res Date: 2010-07-01 Impact factor: 17.367
Authors: Paula A da Costa Martins; Meriem Bourajjaj; Monika Gladka; Mara Kortland; Ralph J van Oort; Yigal M Pinto; Jeffery D Molkentin; Leon J De Windt Journal: Circulation Date: 2008-09-22 Impact factor: 29.690
Authors: Oktay Tutarel; Seema Dangwal; Julia Bretthauer; Mechthild Westhoff-Bleck; Philipp Roentgen; Stefan D Anker; Johann Bauersachs; Thomas Thum Journal: Int J Cardiol Date: 2011-12-20 Impact factor: 4.164
Authors: P Richardson; W McKenna; M Bristow; B Maisch; B Mautner; J O'Connell; E Olsen; G Thiene; J Goodwin; I Gyarfas; I Martin; P Nordet Journal: Circulation Date: 1996-03-01 Impact factor: 29.690
Authors: Anke J Tijsen; Esther E Creemers; Perry D Moerland; Leon J de Windt; Allard C van der Wal; Wouter E Kok; Yigal M Pinto Journal: Circ Res Date: 2010-02-25 Impact factor: 17.367
Authors: Anna Zampetaki; Stefan Kiechl; Ignat Drozdov; Peter Willeit; Ursula Mayr; Marianna Prokopi; Agnes Mayr; Siegfried Weger; Friedrich Oberhollenzer; Enzo Bonora; Ajay Shah; Johann Willeit; Manuel Mayr Journal: Circ Res Date: 2010-07-22 Impact factor: 17.367
Authors: Thomas Thum; Paolo Galuppo; Christian Wolf; Jan Fiedler; Susanne Kneitz; Linda W van Laake; Pieter A Doevendans; Christine L Mummery; Jürgen Borlak; Axel Haverich; Carina Gross; Stefan Engelhardt; Georg Ertl; Johann Bauersachs Journal: Circulation Date: 2007-07-02 Impact factor: 29.690
Authors: Rocío Toro; Sara Blasco-Turrión; Francisco José Morales-Ponce; Pablo Gonzalez; Pablo Martínez-Camblor; Amador López-Granados; Ramon Brugada; Oscar Campuzano; Alexandra Pérez-Serra; Felix Rosa Longobardo; Alipio Mangas; Vicenta Llorente-Cortes; David de Gonzalo-Calvo Journal: J Mol Med (Berl) Date: 2018-07-14 Impact factor: 4.599
Authors: Jonathan Rice; Henry Roberts; James Burton; Jianmin Pan; Vanessa States; Shesh N Rai; Susan Galandiuk Journal: PLoS One Date: 2015-04-08 Impact factor: 3.240